Patents by Inventor Fernando Pérez Cerdá

Fernando Pérez Cerdá has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for the diagnosis and prognosis of demyelinating diseases
    Patent number: 7879568
    Abstract: The present invention refers to the use of glutamate transporters, glutamate and EGF to detect the presence of demyelinating diseases in a subject, to determine the status or severity of the same or to monitor the effects of a therapy administered to a subject who suffers from such diseases; to the use of the said markers for the searching, identification, development and evaluation of the efficacy of compounds for the treatment of such diseases, with a view to developing new drugs; to the use of compounds which promote the expression of the EAAT1 and EAAT2 transporters, as well as EGF for the treatment of demyelinating diseases. In a preferred embodiment, the methods and compounds of the invention are applicable to MS.
    Type: Grant
    Filed: May 22, 2006
    Date of Patent: February 1, 2011
    Assignee: Universidad Del Pais Vasco
    Inventors: Carlos Matute Almau, María Domercq García, Alberto Pérez Samartín, Fernando Pérez Cerdá, Ainara Vallejo Illarramendi, Estibaliz Etxebarria Galnares, Ormaetxea Olatz Pampliega, Pablo Villoslada Díaz, Alfredo Rodríguez-Antigüedad Zarranz
  • Method For the Diagnosis and Prognosis of Demyelinating Diseases and For the Development of Medicaments Against Demyelinating Diseases
    Publication number: 20080200384
    Abstract: The present invention refers to the use of glutamate transporters, glutamate and EGF to detect the presence of demyelinating diseases in a subject, to determine the status or severity of the same or to monitor the effects of a therapy administered to a subject who suffers from such diseases; to the use of the said markers for the searching, identification, development and evaluation of the efficacy of compounds for the treatment of such diseases, with a view to developing new drugs; to the use of compounds which promote the expression of the EAAT1 and EAAT2 transporters, as well as EGF for the treatment of demyelinating diseases. In a preferred embodiment, the methods and compounds of the invention are applicable to MS.
    Type: Application
    Filed: May 22, 2006
    Publication date: August 21, 2008
    Applicant: UNIVERSIDAD DEL PAlS VASCO
    Inventors: Carlos Matute Almau, Maria Domercq Garcia, Alberto Perez Samartin, Fernando Perez Cerda, Ainara Vallejo Illarramendi, Estibaliz Etxebarria Galnares, Ormaetxea Olatz Pampliega, Pablo Villoslada Diaz, Alfredo Rodriguez-Antiguedad Zarranz
  • Compounds for the treatment of demyelinating and autoimmune diseases
    Publication number: 20070099863
    Abstract: The present invention is related to the treatment of demyelinating and autoimmune diseases, more particularly with the treatment of multiple sclerosis. The treatment consists of the administration of P2X purinergic receptors antagonist substances which cause a remission of the symptoms common to these types of diseases. This is demonstrated in in vitro cell models as well as in animal models.
    Type: Application
    Filed: August 4, 2004
    Publication date: May 3, 2007
    Inventors: Carlos Matute Almau, Elena Alberdi Alfonso, Maria Domerco Garica, Alberto Perez Samartin, Fernando Perez Cerda, Iratxe Torre Martinez, Maria Sanchez Gomez